Condensed Balance Sheets - USD ($)	Mar. 31, 2021	Dec. 31, 2020
Current assets:
Cash	$ 348,012,000	$ 138,483,000
Restricted cash	34,650,000	34,650,000
Grants receivable		238,000
Unbilled grants receivable		233,000
Prepaid research and development expenses	5,212,000	12,014,000
Prepaid expenses and other current assets	3,448,000	3,106,000
Total current assets	391,322,000	188,724,000
Property and equipment, net	9,712,000	9,114,000
Operating lease right-of-use-assets	400,000	567,000
Other long term assets	1,748,000
Total assets	403,182,000	198,405,000
Current liabilities:
Accounts payable	10,826,000	4,906,000
Accrued compensation	4,835,000	2,738,000
Accrued expenses and other current liabilities	30,697,000	7,694,000
Current operating lease liabilities	491,000	693,000
Total current liabilities	46,849,000	16,031,000
Commitments and contingencies (Note 5)
Convertible preferred stock		290,945,000
Stockholders’ equity (deficit):
Common stock, $0.0001 par value; 200,000,000 and 230,000,000 shares authorized at March 31, 2021 and December 31, 2020, respectively; 25,637,581 and 2,126,254 shares issued and outstanding at March 31, 2021 and December 31, 2020, respectively	2,000
Additional paid-in capital	589,726,000	64,335,000
Accumulated deficit	(233,398,000)	(172,906,000)
Total stockholders’ equity (deficit)	356,333,000	(108,571,000)
Total liabilities, convertible preferred stock and stockholders’ equity (deficit)	403,182,000	$ 198,405,000
Series 1 Convertible Preferred Stock
Stockholders’ equity (deficit):
Convertible preferred stock	$ 3,000